Search Results for "Breast"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Breast. Results 271 to 280 of 485 total matches.

Famciclovir for Herpes Zoster

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 1994  (Issue 934)
safety during pregnancy or breast feeding is unknown. DOSAGE — The recommended dosage of famciclovir ...
Famciclovir (Famvir - SmithKline Beecham) is now available in the USA for oral treatment of acute uncomplicated herpes zoster (shingles). The manufacturer claims that use of the drug reduces the duration of postherpetic neuralgia. Famciclovir is similar to acyclovir (Zovirax - Burroughs Wellcome), which has been the drug of choice for treatment of varicella-zoster and herpes simplex virus infections (Medical Letter, 36:27, 1994).
Med Lett Drugs Ther. 1994 Oct 28;36(934):97-8 |  Show IntroductionHide Introduction

Cholesterol-lowering margarine

   
The Medical Letter on Drugs and Therapeutics • Jun 18, 1999  (Issue 1055)
and alpha-tocopherol. Phytosterol is found in breast milk and in the plasma of nursing infants. DOSAGE ...
Two cholesterol-lowering margarines have been marketed in the USA.
Med Lett Drugs Ther. 1999 Jun 18;41(1055):56-8 |  Show IntroductionHide Introduction

Correction: Resperate for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Aug 27, 2007  (Issue 1268)
) for HIV Lapatinib (Tykerb) for Breast Cancer Coming Soon in Treatment Guidelines: Drugs for Sexually ...
(Med Lett Drugs Ther 2007; 49:55) The second sentence in the article ("The FDA does not require proof of effectiveness for approval of devices with minimal potential for harm, such as this one.") should have been omitted. It would apply to a Class I device, but the FDA has classified Resperate as a Class II device.
Med Lett Drugs Ther. 2007 Aug 27;49(1268):72 |  Show IntroductionHide Introduction

A Combination of Ledipasvir and Sofosbuvir (Harvoni) for Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014  (Issue 1455)
) and breast cancer resistance protein (BCRP), and ledipasvir is an inhibitor of P-gp and BCRP ...
The FDA has approved a fixed-dose combination (Harvoni [har voe' nee] – Gilead) of sofosbuvir and ledipasvir (led' i pas' vir), two oral direct-acting antiviral agents, for treatment of chronic hepatitis C virus (HCV) genotype 1 infection. Genotype 1 is responsible for 70-80% of HCV infections in the US. Sofosbuvir (Sovaldi) was approved earlier for use in combination with other antiviral drugs for treatment of HCV infection. Ledipasvir is a new drug.
Med Lett Drugs Ther. 2014 Nov 10;56(1455):111-2 |  Show IntroductionHide Introduction

Eluxadoline (Viberzi) for Irritable Bowel Syndrome with Diarrhea

   
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016  (Issue 1485)
is a substrate of organic anion transporting polypeptide (OATP) 1B1 and an inhibitor of OATP1B1 and breast ...
The FDA has approved eluxadoline (Viberzi – Actavis), a mu-opioid receptor agonist and delta-opioid receptor antagonist, for oral treatment of adults with irritable bowel syndrome with diarrhea (IBS-D).
Med Lett Drugs Ther. 2016 Jan 4;58(1485):4-5 |  Show IntroductionHide Introduction

A New Abuse-Deterrent Opioid - Xtampza ER

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016  (Issue 1497)
can cause neonatal opioid withdrawal syndrome. Oxycodone is excreted in breast milk and can cause ...
The FDA has approved Xtampza ER (Collegium), a new extended-release, abuse-deterrent capsule formulation of oxycodone, for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Med Lett Drugs Ther. 2016 Jun 20;58(1497):77-8 |  Show IntroductionHide Introduction

Nusinersen (Spinraza) for Spinal Muscular Atrophy

   
The Medical Letter on Drugs and Therapeutics • Mar 27, 2017  (Issue 1517)
injections of the drug. There are no data on the presence of nusinersen in breast milk. DOSAGE ...
The FDA has approved nusinersen (Spinraza – Biogen) for treatment of spinal muscular atrophy (SMA), a hereditary neurodegenerative disease that occurs in about one in every 10,000 births. It is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2017 Mar 27;59(1517):50-2 |  Show IntroductionHide Introduction

L-Glutamine (Endari) for Sickle Cell Disease

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018  (Issue 1539)
or on its presence in human breast milk, its effect on the breastfed infant, or its effect on milk ...
The FDA has approved an oral powder formulation of the amino acid L-glutamine (Endari – Emmaus) to reduce the acute complications of sickle cell disease in patients ≥5 years old. Endari is only the second drug to be approved for use in sickle cell disease; the antimetabolite hydroxyurea (Droxia) was approved 20 years ago. L-glutamine oral powder is also available by prescription as NutreStore for treatment of short bowel syndrome and over the counter as a dietary supplement.
Med Lett Drugs Ther. 2018 Jan 29;60(1539):21-2 |  Show IntroductionHide Introduction

Haegarda - A Subcutaneous C1 Esterase Inhibitor for Prevention of Hereditary Angioedema

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 2018  (Issue 1541)
in human breast milk, or on its effects on milk production or on the breastfed infant are available ...
The FDA has approved Haegarda (CSL Bering), a human plasma-derived C1 esterase inhibitor (C1INH), for prophylaxis against hereditary angioedema (HAE) attacks in adolescents and adults. Haegarda is the fourth C1INH to be approved by the FDA and the second to be approved for HAE prophylaxis. Unlike the other C1INHs, Haegarda is self-administered subcutaneously rather than intravenously.
Med Lett Drugs Ther. 2018 Feb 26;60(1541):39-40 |  Show IntroductionHide Introduction

Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia

   
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019  (Issue 1581)
of glucagon in breast milk or its effects on the breastfed infant or milk production are available. Glucagon ...
The FDA has approved glucagon nasal powder (Baqsimi – Lilly) for treatment of severe hypoglycemia in patients ≥4 years old with diabetes. Baqsimi is the first noninjectable glucagon formulation to become available in the US. Injectable glucagon emergency kits (GlucaGen Hypokit, and generic) have been available for years, but they require reconstitution of the lyophilized powder by the caregiver immediately before injection. An injectable glucagon formulation that does not require reconstitution was recently approved by the FDA (Gvoke) and is expected to become available...
Med Lett Drugs Ther. 2019 Sep 23;61(1581):148-9 |  Show IntroductionHide Introduction